Invivyd, Inc. Files 8-K

Ticker: IVVD · Form: 8-K · Filed: Dec 23, 2025 · CIK: 1832038

Invivyd, INC. 8-K Filing Summary
FieldDetail
CompanyInvivyd, INC. (IVVD)
Form Type8-K
Filed DateDec 23, 2025
Risk Levellow
Pages1
Reading Time2 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

Topics: corporate-filing, 8-K

Related Tickers: IVVD

TL;DR

Invivyd (IVVD) filed a standard 8-K on Dec 23, 2025. No major news, just corporate housekeeping.

AI Summary

Invivyd, Inc. filed an 8-K on December 23, 2025, reporting other events and financial statements. The company, formerly known as Adagio Therapeutics, Inc., is incorporated in Delaware and has its principal executive offices in New Haven, CT. The filing does not detail specific transactions or financial figures but serves as a standard corporate disclosure.

Why It Matters

This filing indicates routine corporate activity and disclosure for Invivyd, Inc., formerly Adagio Therapeutics, Inc., providing transparency to investors regarding its operational status.

Risk Assessment

Risk Level: low — This is a routine 8-K filing with no specific material events or financial disclosures that would inherently increase risk.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing for Invivyd, Inc.?

This 8-K filing on December 23, 2025, is for reporting 'Other Events' and 'Financial Statements and Exhibits' as per standard SEC requirements.

When was Invivyd, Inc. previously known by another name?

Invivyd, Inc. was formerly known as Adagio Therapeutics, Inc., with a date of name change on November 12, 2020.

Where are Invivyd, Inc.'s principal executive offices located?

Invivyd, Inc.'s principal executive offices are located at 209 Church Street, New Haven, CT 06510.

What is Invivyd, Inc.'s fiscal year end?

Invivyd, Inc.'s fiscal year ends on December 31.

What is the SIC code for Invivyd, Inc.?

Invivyd, Inc. has a Standard Industrial Classification (SIC) code of 2836 for BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES).

Filing Stats: 430 words · 2 min read · ~1 pages · Grade level 11 · Accepted 2025-12-23 07:08:26

Key Financial Figures

Filing Documents

01 Other Events

Item 8.01 Other Events. On December 23, 2025, Invivyd, Inc. issued a press release entitled "Invivyd Earns Fast Track Designation for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID." A copy of the press release is filed herewith as Exhibit 99.1 and is incorporated by reference in this Item 8.01.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated December 23, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. INVIVYD, INC. Date: December 23, 2025 By: /s/ Jill Andersen Jill Andersen Chief Legal Officer and Corporate Secretary

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing